Top

05-03-2025 | Dupilumab | Review

Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors

Authors: Alireza Jafarzadeh, Elham Behrangi, Mina Khosravi, Saba Falakeh, Jasmine Khalilnejad Amiri, Azadeh Goodarzi

Abstract

Background

Recent advancements in the treatment of paediatric dermatological conditions have emerged with the introduction of biologics and small molecule inhibitors (SMIs). These therapies target specific inflammatory pathways, which may enhance treatment outcomes for diseases like atopic dermatitis, psoriasis, and alopecia areata.

Objectives

This systematic review seeks to assess the effectiveness and safety of biologics and SMIs for dermatologic conditions in children and adolescents, with an emphasis on randomised clinical trials.

Methods

We performed an extensive literature search across PubMed, Scopus, and Web of Science, following PRISMA guidelines. Studies included in the review were those that analysed systemic treatments using biologics and SMIs in subjects under 18 years of age. We extracted data on participant demographics, treatment regimens, effectiveness outcomes, adverse effects, and follow-up details. The risk of bias in the studies was determined using the Cochrane Risk of Bias Tool (RoB2).

Results

From an initial pool of 1,454 studies, 49 articles fitting the inclusion criteria were identified, encompassing 6372 cases. The review found that biologics such as Dupilumab, along with investigational JAK inhibitors like Abrocitinib and Upadacitinib, exhibited considerable efficacy in treating various conditions, particularly atopic dermatitis and psoriasis. Dupilumab specifically demonstrated significant improvements in both disease severity and quality of life. While most reported adverse events were mild to moderate, some serious adverse events were noted with certain treatments.

Conclusions

Biologics and SMIs show great promise as therapeutic options in paediatric dermatology, offering better efficacy compared to traditional treatments. Despite these encouraging findings, additional research is needed to verify their long-term safety, especially in relation to growth and development in younger patients. Future investigations should aim to include a broader range of patient demographics and dermatological conditions beyond those currently studied.

Almutairi N (2019) Atopic dermatitis and related disorders: special types of presentation. Harper's textbook of pediatric dermatology, vol 20. pp 228–44

AlMutairi N, Nour T (2020) Tofacitinib in pediatric psoriasis: an open-label trial to study its safety and efficacy in children. Dermatology 236(3):191–198. https://doi.org/10.1159/000503062CrossRefPubMed

Bazargan AS, Jafarzadeh A, Nobari NN (2023) Successful treatment of resistant plantar ulcerative lichen planus with tofacitinib: a case report and comprehensive review of the literature. Clin Case Rep 11(10):e8066. https://doi.org/10.1002/ccr3.80666CrossRefPubMedPubMedCentral

Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, Gherardi G, Xiao J, Dingman R, Xu C, Avetisova E (2024) Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol 160(8):805–812

Beck LA, Muraro A, Boguniewicz M, Chen Z, Zahn J, Rodríguez Marco A (2025) Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 155(1):135–143. https://doi.org/10.1016/j.jaci.2024.08.005CrossRefPubMed

Behrangi E, Moodi F, Jafarzadeh A, Goodarzi A (2024) Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: a comprehensive review. Skin Res Technol 30(5):e13718. https://doi.org/10.1111/srt.13718CrossRefPubMedPubMedCentral

Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J et al (2022) Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 23(3):365–383. https://doi.org/10.1007/s40257-022-00683-2CrossRefPubMedPubMedCentral

Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E et al (2021) Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol 35(4):938–947. https://doi.org/10.1111/jdv.17002CrossRefPubMedPubMedCentral

Brogan PA, Hofer M, Kuemmerle-Deschner JB, Kone-Paut I, Roesler J, Kallinich T et al (2019) Rapid and sustained long-term efficacy and safety of canakinumab in patients with cryopyrin-associated periodic syndrome ages five years and younger. Arthritis Rheumatol 71(11):1955–1963. https://doi.org/10.1002/art.41004CrossRefPubMedPubMedCentral

Brogan P, Yeung RSM, Cleary G, Rangaraj S, Kasapcopur O, Hersh AO et al (2022) phase IIa global study evaluating rituximab for the treatment of pediatric patients with granulomatosis with polyangiitis or microscopic polyangiitis. Arthritis Rheumatol 74(1):124–133. https://doi.org/10.1002/art.41901CrossRefPubMed

Chan S, Cornelius V, Chen T, Radulovic S, Wan M, Jahan R et al (2017) Atopic dermatitis anti-IgE paediatric trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials 18(1):136. https://doi.org/10.1186/s13063-017-1809-7CrossRefPubMedPubMedCentral

Chan S, Cornelius V, Cro S, Harper JI, Lack G (2020) Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr 174(1):29–37. https://doi.org/10.1001/jamapediatrics.2019.4476CrossRefPubMed

Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD et al (2020) Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol 182(1):85–96. https://doi.org/10.1111/bjd.18476CrossRefPubMed

Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Sun X, Chen Z et al (2021) Dupilumab provides favourable long-term safety and efficacy in children aged >/= 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 184(5):857–870. https://doi.org/10.1111/bjd.19460CrossRefPubMed

Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G et al (2022) Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol 36(3):422–433. https://doi.org/10.1111/jdv.17792CrossRefPubMed

Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB et al (2023) Dupilumab safety and efficacy in a phase iii open-label extension trial in children 6–11 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb) 13(11):2697–2719. https://doi.org/10.1007/s13555-023-01016-9CrossRefPubMed

De Graaf M, Janmohamed SR, Schuttelaar MLA et al (2022) Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. J Eur Acad Dermatol Venereol 36(11):2153–2165. https://doi.org/10.1111/jdv.18410CrossRefPubMedPubMedCentral

Dodson J, Lio PA (2022) Biologics and small molecule inhibitors: an update in therapies for allergic and immunologic skin diseases. Curr Allergy Asthma Rep 22(12):183–193. https://doi.org/10.1007/s11882-022-01047-wCrossRefPubMedPubMedCentral

Ebisawa M, Kataoka Y, Tanaka A, Nagao M, Laws E, Mortensen E et al (2024) Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 study. Allergol Int 73(4):532–542. https://doi.org/10.1016/j.alit.2024.04.006CrossRefPubMed

Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R et al (2021) Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol 157(10):1165–1173. https://doi.org/10.1001/jamadermatol.2021.2830CrossRefPubMed

Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B et al (2024) Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial. J Am Acad Dermatol 90(6):1232–1239. https://doi.org/10.1016/j.jaad.2023.11.068CrossRefPubMed

Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34(10):2091–2103. https://doi.org/10.1016/j.clinthera.2012.09.009CrossRefPubMed

Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H et al (2023) Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol 40(6):1003–1009. https://doi.org/10.1111/pde.15378CrossRefPubMed

Silverberg JI, Simpson EL, Thyssen JP, et al (2020) Efficacy https://doi.org/10.1001/jamadermatol.2020.1406

Igarashi A, Katsunuma T, Matsumura T, Komazaki H, Nemolizumab JPSG (2023) Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Br J Dermatol 190(1):20–28. https://doi.org/10.1093/bjd/ljad268CrossRefPubMed

Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT et al (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162(1):89–93. https://doi.org/10.1159/000350486CrossRefPubMed

Jafarzadeh A, Pour Mohammad A, Khosravi M, Amiri S, Rasouli A, Keramati H, Goodarzi A (2024a) A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin Res Technol. 30(3):e13642. https://doi.org/10.1111/srt.13642CrossRefPubMedPubMedCentral

Jafarzadeh A, Pour Mohammad A, Keramati H, Zeinali R, Khosravi M, Goodarzi A (2024b) Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials. Stem Cell Res Ther. 15(1):176. https://doi.org/10.1186/s13287-024-03800-6CrossRefPubMedPubMedCentral

Jafarzadeh A, Mohammad AP, Goodarzi A (2024c) A systematic review of case series and clinical trials investigating regenerative medicine for the treatment of vitiligo. J Cosmet Dermatol. https://doi.org/10.1111/jocd.16660CrossRefPubMedPubMedCentral

Jiang Y, Chen Y, Yu Q, Shi Y (2023) Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs 37(1):35–55. https://doi.org/10.1007/s40259-022-00569-zCrossRefPubMedPubMedCentral

Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, Liu J, Sasaki T, Chu AD, Teixeira HD, Saeki H (2022) A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis. JAAD Int 6:27–36

Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K et al (2023) Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study. Dermatol Ther (Heidelb) 13(1):221–234. https://doi.org/10.1007/s13555-022-00842-7CrossRefPubMed

Katoh N, Ikeda M, Ohya Y, Murota H, Hu X, Liu J et al (2024) Safety and efficacy of upadacitinib for atopic dermatitis in japan: analysis of the 3-year phase 3 rising up study. Dermatol Ther (Heidelb) 14(1):213–232. https://doi.org/10.1007/s13555-023-01071-2CrossRefPubMed

Kaufman BP, Alexis AF (2018) Biologics and small molecule agents in allergic and immunologic skin diseases. Curr Allergy Asthma Rep. 18(10):55. https://doi.org/10.1007/s11882-018-0804-8CrossRefPubMed

Krasowska D, Gambichler T, Cortes C, Horev A, Compagno N, Dahale SS et al (2023) Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: two-year results from a phase III double-blind, randomized controlled trial. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.19063CrossRefPubMed

Kuemmerle-Deschner JB (2015) CAPS–pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol 37(4):377–385. https://doi.org/10.1007/s00281-015-0491-7CrossRefPubMed

Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B et al (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70(12):2095–2102. https://doi.org/10.1136/ard.2011.152728CrossRefPubMed

Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C et al (2010) Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. Eur J Dermatol 20(3):323–328. https://doi.org/10.1684/ejd.2010.0911CrossRefPubMed

Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF et al (2015) Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 73(4):594–603. https://doi.org/10.1016/j.jaad.2015.07.002CrossRefPubMed

Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A et al (2011) Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol 64(1):64–70. https://doi.org/10.1016/j.jaad.2010.02.060CrossRefPubMed

Liang Y, Chen YL, Zhao MT, Wang ZY, Li L, Zhang B, Shen CP, Wang S, Xu ZG, Ma L (2019) Pediatric dermatology-Critical approach to the new treatments. Dermatol Ther 32(4):e12801. https://doi.org/10.1111/dth.12801CrossRefPubMed

Liu GH, Chen T, Zhang X, Ma XL, Shi HS (2022) Small molecule inhibitors targeting the cancers. MedComm. 3(4):181. https://doi.org/10.1002/mco2.181CrossRef

Luo X, Ni X, Zhi J, Jiang X, Bai R (2024) Small molecule agents against alopecia: potential targets and related pathways. Eur J Med Chem 5(276):116666. https://doi.org/10.1016/j.ejmech.2024.116666CrossRef

Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC et al (2022a) A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 86(1):122–30. https://doi.org/10.1016/j.jaad.2021.08.066CrossRefPubMed

Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC et al (2022b) Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs. 24(4):377–87. https://doi.org/10.1007/s40272-022-00507-0CrossRefPubMedPubMedCentral

Malaviya AN, Mehra NK (2018) A fascinating story of the discovery & development of biologicals for use in clinical medicine. Indian J Med Res 148(3):263–278. https://doi.org/10.4103/ijmr.IJMR_1471_18CrossRefPubMedPubMedCentral

Maurer M, Casale TB, Saini SS, Ben-Shoshan M et al (2024) Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol 154(1):184–194. https://doi.org/10.1016/j.jaci.2024.01.028CrossRefPubMed

Nazerian A, Jafarzadeh A, Salehi S, Ghasemi M, Goodarzi A (2024) Cyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01590-0CrossRefPubMed

Ocak M, Soyer O, Buyuktiryaki B, Sekerel BE, Sahiner UM (2020) Omalizumab treatment in adolescents with chronic spontaneous urticaria: efficacy and safety. Allergol Immunopathol (Madr) 48(4):368–373. https://doi.org/10.1016/j.aller.2020.03.011CrossRefPubMed

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358(3):241–251. https://doi.org/10.1056/nejmoa066886CrossRefPubMed

Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J et al (2016) Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 74(2):280–7 e1-3. https://doi.org/10.1016/j.jaad.2015.09.056CrossRefPubMed

Paller AS, Siegfried EC, Thaci D, Wollenberg A, Cork MJ, Arkwright PD et al (2020a) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 83(5):1282–93. https://doi.org/10.1016/j.jaad.2020.06.054CrossRefPubMed

Paller AS, Seyger MMB, Alejandro Magarinos G, Bagel J, Pinter A, Cather J et al (2020b) Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 183(2):231–41. https://doi.org/10.1111/bjd.19147CrossRefPubMedPubMedCentral

Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W et al (2020c) Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J Am Acad Dermatol. 82(2):389–97. https://doi.org/10.1016/j.jaad.2019.08.019CrossRefPubMed

Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP et al (2021) A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol 35(2):464–475. https://doi.org/10.1111/jdv.16928CrossRefPubMed

Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD et al (2022a) Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 400(10356):908–19. https://doi.org/10.1016/s0140-6736(22)01539-2CrossRefPubMed

Paller AS, Seyger MMB, Magarinos GA, Pinter A, Cather JC, Rodriguez-Capriles C et al (2022b) Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 158(5):533–41. https://doi.org/10.1001/jamadermatol.2022.0655CrossRefPubMedPubMedCentral

Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J et al (2023) Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, phase 3 study. Dermatol Ther (Heidelb) 13(7):1517–1534. https://doi.org/10.1007/s13555-023-00942-yCrossRefPubMed

Paller AS, Pinter A, Wine Lee L, Aschoff R, Zdybski J, Schnopp C et al (2024a) Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis. Adv Ther. 41(3):1046–61. https://doi.org/10.1007/s12325-023-02753-1CrossRefPubMedPubMedCentral

Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH et al (2024b) Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol. 25(4):655–68. https://doi.org/10.1007/s40257-024-00859-yCrossRefPubMedPubMedCentral

Papp K, Thaci D, Marcoux D, Weibel L, Philipp S, Ghislain PD et al (2017) Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 390(10089):40–49. https://doi.org/10.1016/s0140-6736(17)31189-3CrossRefPubMed

Portincasa P (2016) Colchicine, biologic agents and more for the treatment of familial mediterranean fever. The old, the new, and the rare. Curr Med Chem. 23(1):60–86. https://doi.org/10.2174/0929867323666151117121706CrossRefPubMed

Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397(10290):2169–2181. https://doi.org/10.1016/s0140-6736(21)00589-4CrossRefPubMed

Sidbury R, Alpizar S, Laquer V, Dhawan S, Abramovits W, Loprete L et al (2022) Pharmacokinetics, safety, efficacy, and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents. Dermatol Ther (Heidelb) 12(3):631–642. https://doi.org/10.1007/s13555-021-00678-7CrossRefPubMed

Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G (2010) Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol 63(5):769–774. https://doi.org/10.1016/j.jaad.2009.10.046CrossRefPubMed

Silverberg JI, Simpson EL, Thyssen JP et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 156(8):863–873. https://doi.org/10.1001/jamadermatol.2020.1406CrossRefPubMed

Simpson EL, Sinclair R, Forman S et al (2020a) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 396(10246):255–266. https://doi.org/10.1016/s0140-6736(20)30732-7CrossRefPubMed

Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al (2020b) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 156(1):44–56. https://doi.org/10.1001/jamadermatol.2019.3336CrossRefPubMed

Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Sygula E et al (2024) Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 90(6):1190–1199. https://doi.org/10.1016/j.jaad.2023.12.066CrossRefPubMed

Smith CH, Jabbar-Lopez ZK, Yiu ZZ et al (2017) British association of dermatologists guidelines for biologic therapy for psoriasis. Br J Dermatol 177(3):628–636. https://doi.org/10.1111/bjd.15665CrossRefPubMed

Soriano A, Soriano M, Espinosa G, Manna R, Emmi G, Cantarini L et al (2020) Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome: evidence-based approach and proposal of a practical guide. Front Immunol 3(11):865. https://doi.org/10.3389/fimmu.2020.00865CrossRef

Staubach P, Alvaro-Lozano M, Sekerel BE, Maurer M, Ben-Shoshan M, Porter M et al (2023) Ligelizumab in adolescents with chronic spontaneous urticaria: results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatr Allergy Immunol 34(7):e13982. https://doi.org/10.1111/pai.13982CrossRefPubMed

Thaci D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD et al (2019) Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol 181(6):1177–1189. https://doi.org/10.1111/bjd.18029CrossRefPubMedPubMedCentral

Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A et al (2023) Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol 189(1):23–32. https://doi.org/10.1093/bjd/ljad096CrossRefPubMed

Yi RC, Moran SK, Gantz HY, Strowd LC, Feldman SR (2024) Biologics and small molecule targeted therapies for pediatric alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in the US: a narrative review. Children 11(8):892. https://doi.org/10.3390/children11080892CrossRefPubMedPubMedCentral

Zhao A, Pan C, Li M (2023) Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: opportunities and challenges. Pediatr Investig 7(3):177–190. https://doi.org/10.1002/ped4.12400CrossRefPubMedPubMedCentral

Title: Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors
Authors: Alireza Jafarzadeh
Elham Behrangi
Mina Khosravi
Saba Falakeh
Jasmine Khalilnejad Amiri
Azadeh Goodarzi
Publication date: 05-03-2025
Publisher: Springer International Publishing
Keywords: Dupilumab
Atopic Dermatitis
Omalizumab
Etanercept
Secukinumab
Ixekizumab
Alopecia Areata
Janus Kinase Inhibitors
Vulgar Psoriasis
Lichen Planus
Urticaria
Ustekinumab
Baricitinib
Adalimumab
Tofacitinib
Rituximab
Rituximab
Published in: Inflammopharmacology
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-025-01675-4

Podcast | Sexual health in older age

Springer Medicine

Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors

Abstract

Background

Objectives

Methods

Results

Conclusions

Podcast | Sexual health in older age

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusions

Please log in to get access to this content